Next Phase Newsletter

The firm is a hybrid family office and operating company based on the East Coast. The firm can make investments ranging from approximately $500,000 to $100 million into companies and due to its funding structure has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes around 5-15 investments in a given year.

The firm is looking for companies in sectors of Biotech Therapeutics and Diagnostics, Medtech, Digital Health, R&D Services, and Biotech Other. The firm is willing to consider all indications including orphan diseases, though they have some additional interest/experience is areas of Women’s Health, GI, Oncology and Cardiovascular, and Personalized Medicine including Proteomics and Genomics. The firm is most interested in companies that are in Phase II or later, nearing commercialization where the firm is capable of utilizing its operating company to scale up the company’s sales, marketing and distribution. That being said the firm has made earlier stage investments in the past and is open to considering highly innovative and compelling early stage companies. The firm is also interested in companies developing consumables/reagents, service providers, food and nutraceuticals.

The firm looks to work with management teams with experience and grit and generally looks to take a board seat although it is not a requirement. The firm looks to leverage the use of its operating company to assist the company’s sales marketing and distribution efforts as well as providing assistance in operations management.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a healthcare-focused venture capital firm that was founded in 1982. Its offices are located in the Midwest. The firm has over $200 million in assets under management and is currently investing out of its sixth fund. The firm makes seed and early-stage investments in healthcare companies, with typical initial investment sizes ranging from $250k to $3.5 million, and total investment up to $8 million over the life cycle of a company. Venture Investors is a regional fund and focused on investments in the Midwest.

The firm focuses on early-stage investments in biopharma, medtech, tools/dx and digital health sectors. The firm is interested in platform technologies that can improve patient outcomes while lowering the cost of care.

The firm looks for experienced management teams with previous start-up experience, industry knowledge, and proven track records as well as scientific founders who are committed to building world class management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Founded in 1986 with offices in the US and Ireland, a venture capital firm recently closed its latest fund, the firm’s largest fund to date with over $1.85B. The firm’s size of investment can largely vary; the firm can invest as little as $50K all the way up to hundreds of millions over the life of investment. The firm is open to investment opportunities globally.

The firm is currently interested in novel concepts and platforms across the life sciences. The firm invests in therapeutics, devices, diagnostics, life science tools, and has a lesser interest in technology-led companies in the healthcare IT space (the firm is not interested in service-based/SaaS healthcare IT businesses). The firm has made many investments in these particular areas: infectious disease, mental health, immunology, genomic and biological tools, data sciences and ways of reimagining diagnostics and therapies. The firm prefers early stage opportunities; in therapeutics, the firm focuses on pre-IND technologies.

The firm only invests in privately held companies that have not previously raised a Series A round or a significant seed round. The firm is a highly hands-on, active investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

Established in 1941, a pharmaceutical company is headquartered in Tokyo, Japan, operating globally in terms of R&D, manufacturing, distribution and marketing, with a strong focus on prescription medicines. The corporate investment arm of the company has offices in USA and a headquarter in Tokyo, Japan. The firm has a budget of $140M USD ($15B JPY) to make strategic equity investments in early-stage companies that align with the company’s core business. The firm will invest between $1-5M in seed to mid-stage companies, with Series A being the sweet spot. The firm is open to global opportunities.

The firm is interested in opportunities that are synergistic with their research and development pipeline in neurology and oncology. The firm is interested in pharmaceutical drugs across various modalities, including but not limited to antibodies, peptides, nucleic acids, and cell/gene therapy. The firm is also interested in digital therapeutics, IT solutions, and diagnostics. Within neurology, the firm is strongly interested in (but not limited to) neurodegenerative diseases including Alzheimer’s Disease and Parkinson’s Disease as well as epilepsy and sleep disorders. Within oncology, the firm is interested in solid tumors (breast, liver, lung, etc).

The firm is a flexible investor and can act as a lead or follow-on investor. The corporate venture investment closely collaborates with the firm’s business development and leverages its global network of pharmaceuticals, research universities, etc. to identify and collaborate with cutting-edge opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A medical device company based in California, USA, with offices worldwide is interested in partnering with medical technology companies. Depending on the stage of the company, these partnerships may include follow-on investments in early-stage equity investments, joint technology development, commercial agreements or acquisitions. The firm typically does not act as a lead investor in equity rounds. The firm can partner with companies based anywhere in the world.

The firm is interested in technologies that strategically align with the firm’s core business. Areas of interest include new technology in 2D and 3D imaging, visualization, 3D printing, materials science, and digital health and AI, and diagnostics for oral diseases. The firm generally partners with companies at an early stage of development.

The firm can partner with companies at any stage but the type of partnership depends on the maturity of the company; for example, the firm may form joint development agreements with early stage companies or make equity investments, and for later stage companies may form commercial or distribution agreements.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

A venture capital firm headquartered in Asia with offices in the USA is actively seeking investment opportunities across a wide range of industries. 1/3 of the fund is dedicated to global/USA-based life sciences and healthcare investments, while the rest of the fund will focus on investing in Asia-based companies. In addition, the firm is expecting to close its newest fund later this year. On average, the initial size of investment is in the $2-5M range but the firm has the capacity to invest more in companies they identify as a strong fit. The firm can participate anywhere from Seed to Series B, but Series A is their sweet spot.

The firm is an opportunistic investor and will consider therapeutics, medical devices, diagnostics, and healthcare IT companies. However, the firm will generally avoid single therapeutic assets and those that are pre-clinical or earlier. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in platform plays, or technologies that have implications in multiple disease areas or indications. Examples include novel drug delivery platforms, drug discovery platforms that leverage AI or machine learning, regenerative medicine, etc.

The firm considers the management team’s character and entrepreneurial spirit – more so than the team’s experience – as one of the most important factors in the investment screening process. Each partner of the firm will dedicate their time to become acquainted with the management team and determine their degree of fit. The targeted market and the company’s competitive edge are also important considerations. The firm prefers to act as the lead investor and will seek board representation, but is also open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm based in the USA started a fund to invest in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

The firm focuses on early-stage healthcare IT projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; that provide more meaningful tracking of health metrics for patients (health and wellness analytics); or initiatives at the intersection of molecular diagnostics and bioinformatics that comb genetic blueprints for clinically-relevant patterns (precision medicine).

The firm is an active and engaged investor, and can act as either a lead or co-investor. The firm prefers to lead investments in seed rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.